Andrew Hendifar is a Gastrointestinal physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 462 publications with 14,236 citations (h-index 53); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
Sponsor: Cedars-Sinai Medical Center
- Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
Sponsor: Cantex Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown.
Industry payments
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year202517 payments$15,836openpaymentsdata.cms.gov ↗
- Ipsen Biopharmaceuticals, IncProgram year20258 payments$15,371openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20253 payments$11,275openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Circulating Tumor Cells as the Liquid Biopsy Foray into Noninvasive Colorectal Cancer Screening.
Cancer epidemiology, biomarkers & prevention
Article2026 - Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients.
Cancer research communications
Clinical Trial2025 - Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer.
JCO precision oncology
Article2025
Similar KOLs
Other experts from the same institution or the same specialty.
Raj Makkar, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center
Cristina Ferrone, MD
Cedars-Sinai Medical Center
Stephen Pandol, MD
Cedars-Sinai Medical Center
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH